The detection rate ranges from 47 to 95%2 justifying the recent inclusion of radiolabeled PSMA PET/CT in the 2022 EAU-ESTRO-EANM-ESUR-SIOG prostate cancer guidelines3. The gene discussed is FOLH1; the disease is prostate carcinoma.